Yoon-Koo Kang

Yoon-Koo Kang

University of Ulsan - Ulsan / South Korea
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4704674
울산대학교
person_outline Yoon-Koo Kang's MOST POPULAR ARTICLES
1-) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...The Lancet 376 (9742), 687-697, 201068772010
2-) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialAL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin, JS Kim, R Luo, J Feng, S Ye, ...The lancet oncology 10 (1), 25-34, 200958522009
3-) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...The Lancet 389 (10088), 2492-2502, 201731372017
4-) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12 …YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, ...The Lancet 390 (10111), 2461-2471, 201722272017
5-) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo …AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ...The lancet oncology 20 (2), 282-296, 201916132019